

1 **Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody**
2 **response over time in hospitalized and non-hospitalized patients with COVID-19**

3
4 Erik H. Vogelzang [1,2],^a Floris C. Loeff [3,4],^a Ninotska IL Derksen [3], Simone Kruithof [3], Pleuni
5 Ooijevaar-de Heer [3], Gerard van Mierlo [3], Federica Linty [5], Juk Yee Mok [6], Wim van Esch [6],
6 Sanne de Bruin [7], Alexander P.J. Vlaar [7], AmsterdamUMC COVID-19 biobank study group,^b Bart
7 Seppen [1], Maureen Leeuw [1], Anne J.G. van Oudheusden [8], Anton G.M. Buiting [8], Kin Ki Jim
8 [2,9], Hans Vrieling [10], Francis Swaneveld [10], Gestur Vidarsson [5], C. Ellen van der Schoot [5],
9 Peter Wever [9], Wentao Li [11], Frank van Kuppeveld [11], Jean-Luc Murk [8], Berend Jan Bosch
10 [11], Gerrit-Jan Wolbink [1,3,12], Theo Rispens [3]^c

11
12 [1] Department of Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam,
13 the Netherlands

14 [2] Department of Medical Microbiology and Infection Control, Amsterdam UMC, location AMC, Amsterdam,
15 the Netherlands

16 [3] Department of Immunopathology, Sanquin Research & Landsteiner Laboratory Academic Medical Centre,
17 Amsterdam, the Netherlands

18 [4] Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands

19 [5] Department of Experimental Immunohematology, Sanquin Research & Landsteiner Laboratory Academic
20 Medical Centre, Amsterdam, the Netherlands

21 [6] Sanquin Reagents, Amsterdam, the Netherlands

22 [7] Department of Intensive Care Medicine, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands

23 [8] Department of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, 's Hertogenbosch, the
24 Netherlands

25 [9] Departments of Medical Microbiology, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands

26 [10] Department of Transfusion Medicine, Sanquin Blood Bank, Amsterdam, the Netherlands

27 [11] Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine,
28 Utrecht University, Utrecht, the Netherlands.

29 [12] Department of Rheumatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands

30 a) contributed equally

31 b) see appendix for author list of the study group

32 c) corresponding author: t.rispens@sanquin.nl

33 **Abstract**

34 SARS-CoV-2 infections often cause only mild disease that may evoke relatively low
35 antibody titers compared to patients admitted to hospitals. Generally, total antibody
36 bridging assays combine good sensitivity with high selectivity. Therefore, we developed
37 sensitive total antibody bridging assays for detection of SARS-CoV-2 antibodies to the
38 receptor-binding domain (RBD) and nucleocapsid protein (NP), in addition to conventional
39 isotype-specific assays. Antibody kinetics was assessed in PCR-confirmed hospitalized
40 COVID-19 patients (n=41) and three populations of patients with COVID-19 symptoms not
41 requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n=182),
42 PCR-confirmed hospital care workers (n=47), and a group of longitudinally sampled
43 symptomatic individuals highly suspect of COVID-19 (n=14). In non-hospitalized patients, the
44 antibody response to RBD is weaker but follows similar kinetics as has been observed in
45 hospitalized patients. Across populations, the RBD bridging assay identified most patients
46 correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD
47 bridging assay could be demonstrated before day 12; NP antibodies emerged less
48 consistently. Furthermore, we demonstrated the feasibility of finger prick sampling for
49 antibody detection against SARS-CoV-2 using these assays. In conclusion, the developed
50 bridging assays reliably detect SARS-CoV-2 antibodies in hospitalized and non-hospitalized
51 patients, and are therefore well-suited to conduct seroprevalence studies.

52

53 Introduction

54 In December 2019, the first cases of atypical pneumonia were reported in China.[1]
55 The causative agent was a β -coronavirus; now known as severe acute respiratory
56 syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is related to the human severe acute
57 respiratory syndrome coronavirus 1 (SARS-CoV-1) and BatCoV RaTG13.[2] In the following
58 months, an increase in reverse transcription-polymerase chain reaction (RT-PCR) confirmed
59 cases of coronavirus infectious disease 2019 (COVID-19) were reported in various
60 countries resulting in the World Health Organization (WHO) declaring a pandemic. RT-PCR-
61 based diagnostics requires active virus shedding. As such, many COVID-19 patients that
62 were not hospitalized remain undiagnosed, and the true extent of SARS-CoV-2 infections is
63 unquestionably higher than initially reported.[3,4] This is confirmed by several
64 seroprevalence studies that have since been conducted.[5–7] However, insight into the
65 dynamics and variability of the antibody response in non-hospitalized patient populations,
66 with only mild symptoms remains to be elucidated. Furthermore, the suitability of various
67 assays to assess these – presumably partly rather weak – responses, is a point of concern.

68 The coronavirus comprises four common structural proteins; the spike (S), envelope
69 (E), membrane (M) and nucleocapsid (N) proteins.[8,9] Previous studies on SARS-CoV-1
70 identified the S protein as a major antigen and antibodies against the S protein were
71 demonstrated to have neutralizing capacity.[10–14] The S protein and more specifically
72 the receptor-binding domain (RBD) in subunit S1 in SARS-CoV-2 is reported to be an
73 immunodominant epitope [40], and has been demonstrated to have negligible cross-
74 reactivity with human coronaviruses HKU1, 229E, NL63 and OC43 or Middle East Respiratory
75 Syndrome coronavirus (MERS-CoV) and only to SARS-CoV-1.[15] The N protein (NP) in SARS-
76 CoV-1 is also immunogenic, eliciting an antibody response.[16,17]. Studies on SARS-CoV-1
77 and SARS-CoV-2 reported that antibodies against the N protein appeared earlier than those
78 directed at the S protein.[18–22] Furthermore, in SARS-CoV-2, immune-dominance of the N-
79 antigen in COVID-19 patients was described.[23] Implementing validated serological assays
80 will provide much-needed information on transmission, the ascertainment of the true
81 infection rate, corresponding mortality and morbidity and the immune response. Also, it will
82 allow a better understanding of the dynamics of SARS-CoV-2 in the general population.

83 Here, we describe the development of a serological bridging assay for the detection
84 of antibodies against the RBD and NP of SARS-CoV-2. Bridging assays, or double-antigen

85 sandwich assay, have the advantage of being able to detect antibodies regardless of isotype,
86 which potentially makes these assays maximally sensitive for seroprevalence studies. Here,
87 we used these assays, together with isotype-specific assays, to assess the antibody response
88 in several hospitalized and non-hospitalized COVID-19 patient populations. In particular, we
89 describe the early antibody response to SARS-CoV-2 in non-hospitalized individuals highly
90 suspect of COVID-19, during the symptomatic stages of disease.

91

92 **Materials and Methods**

93 *Samples and patients*

94 Serum or plasma samples obtained from RT-PCR positive SARS-CoV-2 hospitalized
95 and non-hospitalized recovered adult patients (n=182) who underwent plasmapheresis
96 at Sanquin, the national blood bank, Amsterdam, the Netherlands were included.

97 Also, serum samples from hospitalized SARS-CoV-2 RT-PCR confirmed patients
98 (n=41) at the Jeroen Bosch Hospital, Den Bosch, the Netherlands and Amsterdam University
99 Medical Centre, Location AMC, Amsterdam, the Netherlands were included.

100 From the Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands serum samples of
101 SARS-CoV-2 RT-PCR confirmed healthcare workers (HCWs) were obtained (n=47) at various
102 time points. None of the HCWs were admitted to the hospital for COVID-19.

103 From the Amsterdam Rheumatology and immunology Centre, location Reade, The
104 Netherlands, serum samples were obtained at regular intervals in a group of otherwise
105 healthy volunteers which based on recent travel to an endemic area abroad were highly
106 suspect for COVID-19 (n=7) and household contacts (n=2) of this group that did not go
107 abroad. Moreover, serum samples were collected from a SARS-CoV-2 RT-PCR positive
108 volunteer and close contacts, all with no comorbidities. (n=5). All 14 volunteers had
109 symptoms not requiring hospital admission. Samples were collected at regular intervals
110 after the onset of potential COVID-19 disease symptoms. The average age of participants
111 was 31 years (SD 4.2), 7 (50%) were female and none reported relevant comorbidities.

112 Negative control serum samples were included from healthy blood donors collected
113 by Sanquin (n=307). The negative control samples had been collected from the Dutch
114 population before mid-January 2020, thus prior to the first reported SARS-CoV-2 case in the
115 Netherlands (27 February 2020).

116 This study has been conducted in accordance with the ethical principles set out in
117 the declaration of Helsinki and all participants provided written informed consent, if
118 applicable. Approval was obtained from the Medical Ethics Committees from the Academic
119 Medical Center, VU University Medical Center and Elisabeth-TweeSteden Hospital.

120

121 *Development of SARS-CoV-2 RBD and NP based bridging assays*

122 The RBD-mFc and RBD-ST proteins were produced as described by Okba et al.[15]
123 The NP was produced in HEK cells with HAVT20 leader peptide, 10xhis-tag and a BirA-tag as
124 described by Dekkers et al.[24] MaxiSORP microtiter plates (ThermoFisherScientific, US)
125 were coated with 100 μ L per well 0.125 μ g/mL RBD-mFc or NP in PBS overnight
126 at 4°C. Plates were washed five times with PBS supplemented with 0.02% polysorbate-20
127 (PBS-T). Samples were diluted 10-fold in PBS-T supplemented with 0.3% gelatin (PTG) and
128 incubated on the plate (100 μ L) for 1h at room temperature (RT) while shaking. After
129 washing five times with PBS-T, 100 μ L per well biotinylated RBD-ST (EZ-Link Sulfo-NHS-LC-
130 Biotin, Thermo Fisher) or biotinylated NP (via the BirA tag as described in [24]) was added at
131 0.5 μ g/mL or 0.015 μ g/mL, respectively, in PTG and incubated for 1h at RT, followed by
132 incubation for 30 minutes with streptavidin-poly-HRP (Sanquin). Plates were washed five
133 times with PBS-T, and 100 μ L of TMB substrate (100 μ g/mL) and 0.003% (v/v) hydrogen
134 peroxide (Merck, Germany) in 0.11 M sodium acetate buffer (pH 5.5) was added to each
135 well. A total of 100 μ L of 0.2 M H₂SO₄ (Merck, Germany) was added to stop the reaction.
136 Absorbance was measured at 450 nm and 540 nm. The difference was used to evaluate
137 antibody binding. OD values were normalized to readings of a reference serum pool that
138 was included on each plate and reported as nOD.

139

140 *SARS-CoV-2 RBD and NP isotype-specific assays*

141 MaxiSORP microtiter plates were coated with 1.0 μ g/mL RBD-ST or NP, or 4.0 μ g/mL
142 monoclonal mouse antihuman IgM (MH15, Sanquin, the Netherlands) in PBS overnight at
143 4°C. Following washing with PBS-T, samples were diluted 100-fold/200-fold in PTG and
144 incubated for 1h at RT. After washing, 0.5 μ g/mL HRP-conjugated monoclonal mouse
145 antihuman IgG (MH16, Sanquin) or antihuman IgA (MH14, Sanquin) was added, diluted in
146 PTG and incubated for 1h. Following enzymatic conversion of TMB substrate, absorbance
147 was measured at 450 nm and 540 nm and the difference used to evaluate antibody binding

148 as described above. For IgM, the assay was finished using biotinylated RBD-ST as described
149 above for the bridging assay.

150

151 *Data processing and analysis*

152 Statistical analysis were carried out using Graphpad Prism 7.

153

154 **Results**

155 *Total antibody assays*

156 Total antibody bridging assays depend on the multivalency of antibodies of any
157 isotype to generate a bridge between antigen for capture as well as detection. Therefore,
158 antigen coating density is generally a critical parameter. We set up bridging assays for RBD
159 and NP antigens and optimized antigen coating density to obtain optimal differentiation
160 between specific and non-specific signals using a small set of sera from COVID-19 patients
161 and pre-outbreak healthy donors (HD), see Figure S1. A good reproducibility between runs
162 was observed (Figure S1). After an initial evaluation of 80 pre-outbreak samples, we arrived
163 at a cut-off value of 0.1 nOD, anticipated to provide ca. 99% specificity. Subsequent samples
164 were measured, retested if initially positive (>0.1 nOD), and only considered positive if the
165 repeated measurement was also >0.1 nOD. Analogously, a cut-off value of 0.14 nOD was set
166 for the NP bridging assay.

167

168 *Seroprevalence in different study populations*

169 We assessed seroprevalence with the RBD bridging assay (RBD-Ab) and NP bridging assay
170 (NP-Ab) in several different study populations of PCR-confirmed COVID-19 patients as well
171 as pre-outbreak HD. Only two (0.7%) positive samples were detected in pre-outbreak HD
172 (n=307) using the RBD-Ab, whereas seven (2.5%) positive samples were detected using the
173 NP-Ab (Figure 1). In 40 out of 41 (97.5%) and 39 out of 41 (95.1%) hospitalized patients with
174 active, RT-PCR confirmed COVID-19 we detected antibodies against the RBD or NP,
175 respectively. In PCR-confirmed non-hospitalized convalescent HCW's (n=47) antibodies
176 against RBD or NP were detected in 45 (95.7%) and 39 (83.0%) samples, respectively.
177 Antibodies against RBD were detected in 180 (98.9%) and for the NP in 175 (96.2%) of PCR-
178 confirmed convalescent plasmaphereses donors (n=182), which consists both of patients
179 with and without prior hospitalization due to COVID-19. In all but one case, samples

180 negative in the RBD-Ab assay were also negative in the NP-Ab assay (Figure 4). The above-
181 described seroprevalences demonstrated a good overall sensitivity and specificity of the
182 RBD-Ab (98.1% and 99.3%), and somewhat less for the NP-Ab (93.7% and 97.5%).

183

184 *Antibody response at different time points*

185 To study the effect of time on the seroprevalence and antibody levels determined by using
186 the RBD-Ab and the NP-Ab, we stratified the samples of the non-hospitalized cases
187 (plasmapheresis donors and HCWs) for different days since symptom onset (information
188 available for n=167; Figure 2). As comparison, in addition to the hospitalized patients with
189 active disease (approx. 8 – 23 day post symptom onset), convalescent cases that were
190 previously admitted to the hospital are also included (n = 27; approx. 20 – 66 post symptom
191 onset). There is an increase in nOD over time for the RBD-Ab in hospitalized cases and a
192 similar, non-significant trend in non-hospitalized cases. However, there is no apparent effect
193 of time after onset of symptoms on the detection of antibodies in the RBD-Ab or NP-Ab
194 assay.

195 To obtain insight into the dynamics of the different isotypes, we also measured
196 antibodies using assays for the detection of IgM, IgG, and IgA (Figure 2). For the antibody
197 response to the RBD, there is a (non-significant) trend towards declining IgM and IgA levels
198 as time progresses in both hospitalized and non-hospitalized patients. Hospitalized patients
199 have significantly higher IgG levels later in time. In non-hospitalized patients, the IgG
200 response rises slowly over time and gains prominence relative to other isotypes at later time
201 points (Figure S2), in line with expectations. At least up to 60 days after symptom onset
202 substantial amounts of IgG to the RBD can be detected in this population. In comparison to
203 hospitalized convalescent patients, the IgG response in non-hospitalized patients is
204 significantly weaker, as shown in Figure 2. A similarly weaker IgG response is also observed
205 against the NP.

206

207 *Antibody kinetics in non-hospitalized patients at early time points*

208 To obtain a better insight into the antibody response against SARS-CoV-2 and thus the
209 seroprevalence in a in specific population, we tested sequentially collected sera from a
210 group of non-hospitalized and otherwise healthy individuals who were highly suspected of
211 having contracted COVID-19 (Reade patient cohort; Figure 3). Day 3 post symptom onset

212 samples were available for two individuals and were negative in both the bridging assays as
213 well as in the IgM, IgG, and IgA assays. Within 12 days post symptom onset, antibodies
214 against the RBD were detected in 11 out of 14 (78.6%) patients as compared to 8 out of 14
215 (53.1%) against NP antibodies, as shown in Figure 3, using the bridging assays. At day 60,
216 one of the previously negative samples became positive in both bridging assays.

217 Figure 3 shows the antibody kinetics for IgM, IgG and IgA. Most patients (n=9)
218 seroconverted for IgG within 15 days post symptom onset, although three patients
219 seroconverted later. The slow appearance of IgG antibodies to RBD is clearly seen in this
220 population. Interestingly, at two months, IgG anti-RBD appears to be declining again,
221 suggesting a lack of sustained overall anti-RBD response in this group of patients. The
222 antibody response to NP is not detectable in most patients around day 10 both in the NP-Ab
223 and NP-IgG assays, and remains weak in many patients at later time points.

224

225 *Comparison of assay formats*

226 The RBD-Ab assay identifies positive patients most reliably, with few false-positive cases.
227 Sensitivity and/or specificity could theoretically be enhanced by combining two or more
228 assays. When comparing the RBD-Ab with the NP-Ab assay, we observe that for HD, none of
229 the samples were positive in both assays as shown in Figure 4. Requiring both assays to be
230 positive would therefore result in enhanced specificity, albeit with reduced sensitivity. Also,
231 for the RBD-IgG assay it appears that negative control samples either have elevated signals
232 in either this assay or the RBD-Ab, but not both (Figure 5). There is a moderately strong
233 correlation between RBD-Ab and RBD-IgG (Spearman $r = 0.69$, $p < 0.0001$) across the
234 populations; whereas the correlation between RBD-Ab and NP-Ab is moderate ($r = 0.58$,
235 $p < 0.0001$).

236

237 *Finger prick sampling*

238 A relatively low volume of serum is needed for the developed assay to assess the
239 antibody response, therefore making it well suited for finger prick sampling. A small number
240 of samples (n = 11) was obtained by finger prick sampling, rather than obtained by
241 venipuncture. Antibodies were detected by the RBD-Ab assay and compared to a matching
242 venipuncture draw (Figure 6). The results suggest that a finger prick is an equivalent method
243 for drawing blood when using this assay to detect antibodies against the RBD.

244 Discussion

245 In this study, we describe the development of sensitive serological bridging assays
246 based on the RBD and NP to detect antibodies against SARS-CoV-2. Assay performance was
247 evaluated in serum samples of different patient populations (hospitalized and non-
248 hospitalized) and the RBD bridging assay was found to best discriminate between cases and
249 pre-outbreak controls across different time points, especially in individuals with COVID-19
250 symptoms who did not require hospital admission. We also show the early antibody kinetics
251 in a group of non-hospitalized individuals, highly suspected of having contacted COVID-19,
252 during their symptomatic phase. Finally, we demonstrate the feasibility of using finger prick
253 sampling for the detection of antibodies against SARS-CoV-2.

254 In recent studies, seroconversion of SARS-CoV-2 infected hospitalized
255 patients usually occurred between 5-14 days.[15,20,21,25,26] Our study demonstrated a
256 similar result in non-hospitalized patients. Since an adequate antibody response requires
257 time to develop, false-negative results will occur depending on the timing of sampling
258 independent of the type of assay used, thereby influencing seroprevalence study results. In
259 one patient followed over time, seroconversion occurred after day 15. Although this patient
260 went to work (not healthcare related) and did groceries, other public measures regarding
261 SARS-CoV-2 were followed, and this is probably a late seroconversion.

262 In the non-hospitalized patients, the isotype-specific antibody response to RBD
263 follows a pattern similar to hospitalized patients [41], with a relatively late appearance of
264 IgG antibodies. Although the IgG levels are significantly lower in the non-hospitalized
265 population, these antibodies nevertheless are present in readily detectable amounts up to
266 60 days after symptom onset. The long-term persistence of these responses remains to be
267 investigated.

268 Bridging assay, or homologous double-antigen sandwich immunoassays have found
269 firm ground in the assessment of (weak) immune responses against biopharmaceutical
270 drugs [27,28], but are as yet relatively uncommon for measurement of antibodies to viral
271 antigens. Nevertheless, a commercially available assay using a similar format for SARS-CoV-2
272 has been described.[29] Advantages of this assay type include the ability to detect
273 antibodies of any isotype (with the exception of IgG4 [30], which is unlikely to be of
274 relevance in the context of an antiviral immune response) and a generally low background.
275 Disadvantages include the lower responsiveness to low-affinity antibodies. In general, the

276 assay described here is robust in detecting SARS-CoV-2 antibodies in patients with
277 symptoms not requiring hospital admittance. This will aid in determining the true
278 prevalence of COVID-19. The use of this developed assay could, therefore, lead to a better
279 understanding of the dynamics of SARS-CoV-2 infections in the population since it is
280 assumed that a large proportion of COVID-19 patients have mild symptoms and are not
281 hospitalized.

282 In prior publications, mainly in hospitalized patients, the antibody response against
283 the NP appeared earlier than that against the S protein. [18–23] Similarly, a study in SARS-
284 CoV-1 described that the IgG immune response is more frequently directed against the NP
285 compared to the S protein.[31] Moreover, in a SARS-CoV-2 study, it was found that most ICU
286 patients had a higher N-IgG than S –IgG titer compared to non-ICU hospitalized patients.[32]
287 Other studies demonstrated or suggested an association between disease severity and level
288 and/or longevity of the antibody response for SARS-CoV-2 and MERS-CoV.[15,33–35] Our
289 results suggest that the antibody response against the NP of SARS-CoV-2 needs more time
290 to develop compared to the antibody response against the RBD in patients with mild
291 symptoms, and is overall more variable. Our finding regarding the NP may, therefore, be
292 (partially) based on the difference in immune response based on disease severity (e.g.
293 hospitalized and non-hospitalized). However, the discrepancy between our finding and that
294 of previous research needs to be confirmed in a larger sample size, since other factors such
295 as the timing of samples and difference between assay types can also influence this.

296 Since different samples were positive in the RBD-Ab and NP-Ab assays in our healthy
297 donors, there is a rationale for performing both assays to eliminate false positives. This will
298 however result in a somewhat diminished sensitivity. A similar pattern is seen for the RBD-
299 Ab assay compared to the RBD-IgG assay. In another study, combining different antigens has
300 also been proposed to optimize the sensitivity and specificity of a SARS-CoV-2 serological
301 assay.[23] Two-tier testing strategies are regularly implemented for other infectious
302 diseases such as Lyme disease or syphilis.

303 In a recent study describing a SARS-CoV-2 transmission model a range of
304 transmission scenarios were examined and it was suggested that: “serological testing is
305 required to understand the extent and duration of immunity to SARS-CoV-2 which will help
306 determine the post-pandemic dynamics of the virus.”.[36] Determining the true extent of
307 the total incidence of SARS-CoV-2 by serological testing will optimize these transmission

308 models and could aid in determining which public health measures are needed and their
309 timing to maintain control of the SARS-CoV-2 pandemic. To assess this during periods of
310 widespread transmission and when non-essential travel is prohibited, we developed a
311 reliable serological assay which needs a low volume of serum and is therefore well suited to
312 use for blood obtained by finger prick.

313 There are some limitations to this study. Further investigation of cross-reactivity
314 for the different coronaviruses may be necessary since the RBD of SARS-CoV-2 may show
315 cross-reactivity with other human coronaviruses (HCoV), and in particular SARS-CoV-1.
316 However, we anticipate that this will not alter our findings due to the limited number of
317 cases with SARS-CoV-1 in Europe. [37] By including a large population of healthy controls
318 the risk of having missed substantial cross-reactivity against other HCoV is also limited;
319 especially since antibodies against HCoV are detected in the majority of the population
320 (>90% for all four HCoV).[38,39]

321 Furthermore, although this study provides an insight into the antibody response in
322 the early phase of infection in non-hospitalized patients, the number of cases is still modest.
323 Our study describes the early antibody kinetics in a population based on probable exposure
324 and not based on symptoms or hospitalized patients who are RT-PCR positive. Yet, this
325 provides an unbiased view of the performance of the developed serological assay and the
326 antibody response in patients with mild SARS-CoV-2 infection.

327 In summary, this study demonstrates the use of a sensitive bridging assay to study
328 seroprevalence in non-hospitalized COVID-19 patients, and provides insight into the early
329 kinetics of the antibody response to SARS-CoV-2 in this population.

330

331 **Author contributions**

332 GW, TR conceived of the study, EHV, FCL, BS, BJB, GW, TR were involved in study design and
333 organization, NILD, SK, POH, GvM, FL, JYM, WL conducted experiments, EHV, FCL, TR
334 analyzed data, EHV, FCL, GV, GW, TR wrote the paper, TR supervised the study, all authors
335 provided critical revision of the paper.

336 **References**


- 337 1 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in
338 China, 2019. *N Engl J Med* 2020;**382**:727–33. doi:10.1056/NEJMoa2001017
- 339 2 Zhou P, Yang X-L, Wang X-G, *et al.* A pneumonia outbreak associated with a new
340 coronavirus of probable bat origin. *Nature* 2020;**579**:270–3. doi:10.1038/s41586-020-
341 2012-7
- 342 3 Li R, Pei S, Chen B, *et al.* Substantial undocumented infection facilitates the rapid
343 dissemination of novel coronavirus (SARS-CoV-2). *Science (80-)* 2020;**368**:489 LP-493.
344 doi:10.1126/science.abb3221
- 345 4 Wu JT, Leung K, Bushman M, *et al.* Estimating clinical severity of COVID-19 from the
346 transmission dynamics in Wuhan, China. *Nat Med* 2020;**26**:506–10.
347 doi:10.1038/s41591-020-0822-7
- 348 5 To KK-W, Cheng VC-C, Cai J-P, *et al.* Seroprevalence of SARS-CoV-2 in Hong Kong and
349 in residents evacuated from Hubei province, China: a multicohort study. *The Lancet*
350 *Microbe* 2020;**0**. doi:10.1016/S2666-5247(20)30053-7
- 351 6 Slot E, Hogema B, Reusken C, *et al.* Herd immunity is not a realistic exit strategy
352 during a COVID-19 outbreak. 2020. doi:10.21203/rs.3.rs-25862/v1
- 353 7 Sood N, Simon P, Ebner P, *et al.* Seroprevalence of SARS-CoV-2–Specific Antibodies
354 Among Adults in Los Angeles County, California, on April 10-11, 2020. *JAMA* Published
355 Online First: 18 May 2020. doi:10.1001/jama.2020.8279
- 356 8 Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis.
357 *Methods Mol Biol* 2015;**1282**:1–23. doi:10.1007/978-1-4939-2438-7_1
- 358 9 Rota PA, Oberste MS, Monroe SS, *et al.* Characterization of a Novel Coronavirus
359 Associated with Severe Acute Respiratory Syndrome. *Science (80-)* 2003;**300**:1394 LP-
360 1399. doi:10.1126/science.1085952
- 361 10 Berry JD, Jones S, Drebot MA, *et al.* Development and characterisation of neutralising
362 monoclonal antibody to the SARS-coronavirus. *J Virol Methods* 2004;**120**:87–96.
363 doi:10.1016/J.JVIROMET.2004.04.009
- 364 11 Traggiai E, Becker S, Subbarao K, *et al.* An efficient method to make human
365 monoclonal antibodies from memory B cells: potent neutralization of SARS
366 coronavirus. *Nat Med* 2004;**10**:871–5. doi:10.1038/nm1080
- 367 12 Sui J, Li W, Murakami A, *et al.* Potent neutralization of severe acute respiratory

- 368 syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor
369 association. *Proc Natl Acad Sci* 2004;**101**:2536–41. doi:10.1073/PNAS.0307140101
- 370 13 Hofmann H, Hattermann K, Marzi A, *et al.* S Protein of Severe Acute Respiratory
371 Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is
372 Targeted by Neutralizing Antibodies in Infected Patients. *J Virol* 2004;**78**:6134 LP-
373 6142. doi:10.1128/JVI.78.12.6134-6142.2004
- 374 14 Buchholz UJ, Bukreyev A, Yang L, *et al.* Contributions of the structural proteins of
375 severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl*
376 *Acad Sci U S A* 2004;**101**:9804 LP-9809. doi:10.1073/pnas.0403492101
- 377 15 Okba NMA, Muller MA, Li W, *et al.* Severe Acute Respiratory Syndrome Coronavirus
378 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerg Infect Dis*
379 2020;**26**. doi:10.3201/eid2607.200841
- 380 16 Chen Z, Pei D, Jiang L, *et al.* Antigenicity analysis of different regions of the severe
381 acute respiratory syndrome coronavirus nucleocapsid protein. *Clin Chem*
382 2004;**50**:988–95. doi:10.1373/clinchem.2004.031096
- 383 17 Qiu M, Shi Y, Guo Z, *et al.* Antibody responses to individual proteins of SARS
384 coronavirus and their neutralization activities. *Microbes Infect* 2005;**7**:882–9.
385 doi:10.1016/j.micinf.2005.02.006
- 386 18 Tan Y-J, Goh P-Y, Fielding BC, *et al.* Profiles of antibody responses against severe
387 acute respiratory syndrome coronavirus recombinant proteins and their potential use
388 as diagnostic markers. *Clin Diagn Lab Immunol* 2004;**11**:362–71.
389 doi:10.1128/cdli.11.2.362-371.2004
- 390 19 Woo PCY, Lau SKP, Wong BHL, *et al.* Differential sensitivities of severe acute
391 respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked
392 immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for
393 serodiagnosis of SARS coronavirus pneumonia. *J Clin Microbiol* 2005;**43**:3054–8.
394 doi:10.1128/JCM.43.7.3054-3058.2005
- 395 20 Zhao J, Yuan Q, Wang H, *et al.* Antibody responses to SARS-CoV-2 in patients of novel
396 coronavirus disease 2019. *Clin Infect Dis* Published Online First: March 2020.
397 doi:10.1093/cid/ciaa344
- 398 21 Guo L, Ren L, Yang S, *et al.* Profiling Early Humoral Response to Diagnose Novel
399 Coronavirus Disease (COVID-19). *Clin Infect Dis an Off Publ Infect Dis Soc Am*

- 400 Published Online First: March 2020. doi:10.1093/cid/ciaa310
- 401 22 Grzelak L, Temmam S, Planchais C, *et al.* SARS-CoV-2 serological analysis of COVID-19
402 hospitalized patients, pauci-symptomatic individuals and blood donors. *medRxiv*
403 2020;:2020.04.21.20068858. doi:10.1101/2020.04.21.20068858
- 404 23 Hachim A, Kavian N, Cohen CA, *et al.* Beyond the Spike: identification of viral targets
405 of the antibody response to SARS-CoV-2 in COVID-19 patients. *medRxiv*
406 2020;:2020.04.30.20085670. doi:10.1101/2020.04.30.20085670
- 407 24 Dekkers G, Treffers L, Plomp R, *et al.* Decoding the Human Immunoglobulin G-Glycan
408 Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector
409 Activities. *Front Immunol* 2017;**8**:877. doi:10.3389/fimmu.2017.00877
- 410 25 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized
411 patients with COVID-2019. *Nature* Published Online First: 2020. doi:10.1038/s41586-
412 020-2196-x
- 413 26 To KK-W, Tsang OT-Y, Leung W-S, *et al.* Temporal profiles of viral load in posterior
414 oropharyngeal saliva samples and serum antibody responses during infection by
415 SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* Published Online First:
416 March 2020. doi:10.1016/S1473-3099(20)30196-1
- 417 27 Bloem K, Hernández-breijó B, Martínez-feito A, *et al.* Immunogenicity of Therapeutic
418 Antibodies: Monitoring Antidrug Antibodies in a Clinical Context. *Ther Drug Monit*
419 2017;**39**:327–32.
- 420 28 Gorovits B, Baltrukonis DJ, Bhattacharya I, *et al.* Immunoassay methods used in
421 clinical studies for the detection of anti-drug antibodies to adalimumab and
422 infliximab. *Clin Exp Immunol* 2018;**192**:348–65. doi:10.1111/cei.13112
- 423 29 Lassaunière R, Frische A, Harboe ZB, *et al.* Evaluation of nine commercial SARS-CoV-2
424 immunoassays. *medRxiv* 2020;:2020.04.09.20056325.
425 doi:10.1101/2020.04.09.20056325
- 426 30 Hart MH, de Vrieze H, Wouters D, *et al.* Differential effect of drug interference in
427 immunogenicity assays. *J Immunol Methods* 2011;**372**:196–203.
428 doi:<https://doi.org/10.1016/j.jim.2011.07.019>
- 429 31 Leung DTM, Chi Hang TF, Chun Hung M, *et al.* Antibody Response of Patients with
430 Severe Acute Respiratory Syndrome (SARS) Targets the Viral Nucleocapsid. *J Infect Dis*
431 2004;**190**:379–86. doi:10.1086/422040

- 432 32 Sun B, Feng Y, Mo X, *et al.* Kinetics of SARS-CoV-2 specific IgM and IgG responses in
433 COVID-19 patients. *Emerg Microbes Infect* 2020;:1–36.
434 doi:10.1080/22221751.2020.1762515
- 435 33 Choe PG, Perera RAPM, Park WB, *et al.* MERS-CoV Antibody Responses 1 Year after
436 Symptom Onset, South Korea, 2015. *Emerg Infect Dis* 2017;**23**:1079–84.
437 doi:10.3201/eid2307.170310
- 438 34 Alshukairi AN, Khalid I, Ahmed WA, *et al.* Antibody Response and Disease Severity in
439 Healthcare Worker MERS Survivors. *Emerg Infect Dis* 2016;**22**.
440 doi:10.3201/eid2206.160010
- 441 35 Drosten C, Meyer B, Muller MA, *et al.* Transmission of MERS-coronavirus in
442 household contacts. *N Engl J Med* 2014;**371**:828–35. doi:10.1056/NEJMoa1405858
- 443 36 Kissler SM, Tedijanto C, Goldstein E, *et al.* Projecting the transmission dynamics of
444 SARS-CoV-2 through the postpandemic period. *Science (80-)* 2020;:eabb5793.
445 doi:10.1126/science.abb5793
- 446 37 World Health Organisation. China’s latest SARS outbreak has been contained, but
447 biosafety concerns remain – Update 7.
448 https://www.who.int/csr/don/2004_05_18a/en/ (accessed 15 Apr 2020).
- 449 38 Gorse GJ, Patel GB, Vitale JN, *et al.* Prevalence of Antibodies to Four Human
450 Coronaviruses Is Lower in Nasal Secretions than in Serum. *Clin Vaccine Immunol*
451 2010;**17**:1875 LP-1880. doi:10.1128/CVI.00278-10
- 452 39 Severance EG, Bossis I, Dickerson FB, *et al.* Development of a Nucleocapsid-Based
453 Human Coronavirus Immunoassay and Estimates of Individuals Exposed to
454 Coronavirus in a U.S. Metropolitan Population. *Clin Vaccine Immunol* 2008;**15**:1805
455 LP-1810. doi:10.1128/CVI.00124-08
- 456 40 Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A,
457 Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Roupheal N,
458 Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J,
459 Baric RS, de Silva AM. The receptor binding domain of the viral spike protein is an
460 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci*
461 *Immunol.* 2020 Jun 11;5(48):eabc8413. doi: 10.1126/sciimmunol.abc8413.
- 462 [41] Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, Quentric P, Fadlallah J,
463 Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt C, Mayaux J, Beurton A,

464 Fourati S, Lacorte J, Yssel H, Parizot C, Dorgham K, Charneau P, Amoura Z, Gorochov G,
465 IgA dominates the early neutralizing antibody response to SARS-CoV-2, *medRxiv.org*,
466 *2020.06.10.20126532*
467



468

469

470 **Figure 1.** Total antibody titers measured in different patient populations.

471 Total antibody titers against the RBD (A) and NP (B) measured in different patient


472 populations: pre-outbreak healthy donors (HD), hospitalized active-disease patients (Hosp.

473 Ac), non-hospitalized, convalescent healthcare workers (HCW Conv) and convalescent

474 plasmapheresis donors (PD Conv). Samples below the lower dotted line are considered

475 negative, whereas the upper dotted line indicates upper boundary of dynamic range.

476




477
478

479 **Figure 2.** Antibody titers and isotypes measured in different patient populations and at
480 various time points.

481 Total and isotype-specific antibody titers against the RBD and NP were measured in
482 different patient populations: hospitalized patients with active disease (Hosp. Ac; 8 – 23
483 days post symptom onset; n = 41) or convalescent cases (Hosp. Conv; 20 – 66 days post
484 symptom onset; n = 27), and non-hospitalized convalescent individuals (Non-Hosp. Conv; n =
485 167). For the latter group, on the x axes the number of days post symptom onset are
486 indicated. For the isotype-specific assays, signals measured in pre-outbreak healthy donors
487 (HD) are also indicated (for total Ab, see Figure 1). Dotted lines indicate approximate 95%
488 (IgM) and 98% (IgG, IgA) percentile of the negative controls. * p < 0.05; ** p < 0.01; *** <
489 0.001. Tests performed: Hosp. Ac vs Hosp. Conv, Mann-Whitney; Hosp. Conv vs Non-Hosp.
490 Conv, Kruskal-Wallis test/Dunn's multiple comparisons test.

491



492

493 **Figure 3.** Kinetics of antibody response against SARS-CoV-2.

494 In 14 non-hospitalized patients with mild symptoms and a high likelihood (1 SARS-CoV-2 RT-

495 PCR confirmed) of SARS-CoV-2 infection we tested the antibody response against the RBD-


496 Ab, NP-Ab, NP-IgG, RDB-IgM, RBD-IgG and RBD-IgA. The x-axes show the number of days

497 post symptom onset. The horizontal dotted line is the cut-off; samples below this line are

498 considered negative. The vertical dotted lines represent from left to right 8 days, 13 days

499 and 19 days post symptom onset.

500




501

502 **Figure 4.** Anti-NP and RBD immune responses compared.

503 Antibodies detected with the NP-Ab and the RBD-Ab assay plotted on the x-y axes for
504 different patients groups: pre-outbreak healthy donors (HD), hospitalized patients with
505 active disease(Hosp. Ac) or convalescent cases (Hosp. Conv), non-hospitalized convalescent
506 individuals (Non-Hosp. Conv, and the Reade patient cohort (R); stratified according to days
507 post symptom onset as indicated. Dotted lines indicate the cut-off for both assays.

508




509

510

511 **Figure 5.** Comparison between the RBD-Ab and RBD-IgG assay.

512 Comparison of the detection of antibodies with the RBD-Ab and RBD-IgG assay plotted on
513 the x-y axes for different patient groups; stratified according to days post symptom onset as
514 indicated. Dotted lines indicate the cut-off for both assays.

515




516

517 **Figure 6.** Comparison of venipuncture and finger prick.

518 For the RBD-Ab we compared the antibody titers measured in eleven serum samples

519 obtained from a venipuncture and that obtained by finger prick.


520



521

522 **Figure S1.** Setup of total antibody bridging assays for A) RBD and D) NP antigen. B,E) Impact
523 of coating density on signals obtained from sera of selected COVID-19 patients and pre-
524 outbreak controls for B) RBD, and E) NP. C,F) Correlation between two independent runs for
525 C) the RBD-Ab assay, and F) the NP-Ab assay.

526



527

528 **Figure S2.** Gain in anti-RBD IgG over other isotypes over time in the non-hospitalized

529 convalescent individuals. Ratio of nODs. * $p < 0.05$; ** $p < 0.01$; Kruskal-Wallis test/Dunn's

530 multiple comparisons test.

531